Medical information was obtained from the patient records.
treatment modalities. [5] [6] [7] [8] [9] [10] In testicular cancer patients, can still occur even after castration. 34, 35 The exact consequences of subnormal testosterone levels on orgasm much attention has been focused on the possible physiologic consequences on overt sexual behavior and ejaculation are current topics of discussion. 32, 36, 37 Radiotherapy (RT) may decrease Leydig cell function-(erection, coitus, and ejaculation). It is only during the past decade that the evaluation of sexuality in terms ing in the remaining testicle [38] [39] [40] or testosterone production. 41, 42 Although the penile blood vessels lie out-of its more subjective aspects (libido, arousal, orgasm, and satisfaction) [11] [12] [13] have entered the discussion. [14] [15] [16] [17] [18] [19] [20] [21] [22] side the radiation field, erectile dysfunction may be related to radiation damage to the small blood vessels Data on sexual functioning after treatment for testicular cancer vary widely and only a few studies ana-and nerves that regulate the penile blood supply. [43] [44] [45] Polychemotherapy (PCT) may decrease testosterone lyzed the results of sexual functioning in connection with the treatment applied. 14,15,18 -20,22,23 However, levels through Leydig cell damage within the remaining testicle, 43 or by hyperprolactinemia. 46 How-comparison of outcomes is difficult due to lack of conformity regarding treatment regimens, composition of ever, Leydig cell dysfunction probably is temporary. 47 Erectile dysfunction may be related to PCT-induced the patient groups, and research questions in the various studies. For example, in some studies, a major risk vascular damage. 16,48 -50 In addition, theoretically, decreased ejaculation, erectile dysfunction, or orgasmic factor for sexual dysfunction was found to be irradiation; 18 -20,22 in others it was found to be chemother-difficulties may also be related to PCT-induced peripheral neuropathy. 16, 49 apy. 15, 23, 24 Some studies assume that there are no differences between different treatment groups. 14, 25 One
In patients treated by resection of residual retroperitoneal tumor mass after PCT (PCT/RRRTM), 6 -study found no differences between irradiated patients when compared with patients under surveillance only, 30% reported ejaculatory disturbances. [51] [52] [53] [54] [55] It is unknown whether retrograde ejaculation has a negative but found significant differences when these same patients were compared with healthy controls, 20 whereas influence on the intensity of orgasm. 56 In the case of reduced orgasmic intensity in patients treated by PCT in another study there were no significant differences between patients under surveillance and healthy con-and RRRTM, it is most likely not the retrograde ejaculation, but PCT that is responsible. 24, 57 Because the trols. 26 Therefore, it is not quite clear whether and to what extent physiologic consequences of a particular parasympathetic nerve tracts that regulate erection lie outside the area of RRRTM, the same may be true in treatment, or emotional and cognitive consequences, influence sexual functioning.
the case of erectile disturbances after PCT/RRRTM. To gain better insight into possible changes in the subjective experience of sexuality after testicular can-
METHODS

cer, as well as the influence of various treatment mo-Patients and Treatments
dalities, a study was performed on patients who were All patients who had been treated for a malignant testreated for testicular cancer at the University Hospital ticular germ cell tumor between 1977 -1994 at the Uni-Groningen between 1977 -1994. In this study, the folversity Hospital Groningen and who were still alive, lowing two questions played a central role: 1) To what were approached by means of a written questionnaire extent does testicular cancer and/or its treatment lead (n Å 337). The patients were informed about the use to changes in sexual functioning; and 2) To what extent of the data by a cover letter wherein it was emphasized are there differences in sexual functioning after treatthat nonresponse would not affect treatment. On a ment between the various treatment groups. separate form patients could indicate whether they wished to receive information about the results of the Treatment-Related Biologic-Organic Influences on Sexual study. Permission to perform the study had been ob-Functioning tained from the Medical Ethical Committee. To examine the extent to which biologic-organic as-Two histologic types of testicular tumor were dispects relevant to sexual functioning may become distinguished: seminoma (ST) and nonseminomatous turbed after treatments for testicular cancer, an extengerm cell tumors (NSGCT); ST is generally diagnosed sive search of the literature was performed on the posat a later age (40 -50 years) than NSGCT. Patients were sible hormonal, vascular, or neurologic changes. 27 staged according to the Royal Marsden Hospital Stag-After unilateral orchidectomy, decreased testosing Classification, 58 as follows: Stage I: no metastases terone levels were found in 5 -34% of patients, probaevident outside testis; Stage II: infradiaphragmatic bly due to preexisting abnormalities in the remaining lymph node metastasis (IIA: õ 2 cm; IIB: 2 -5 cm; testicle. [28] [29] [30] [31] However, normal sexual functioning is and IIC: ú 5 cm); Stage III: supradiaphragmatic lymph possible even with very low serum testosterone levels (6 -12 nmol/L), 32 , which was comprised activity were measured by combining the questions of physical check-ups, screening for elevated tumor on sexual activity before the diagnosis and currently; markers, and computed tomography scanning. 59 Pain this way, a 7-point scale was obtained, from ''sharp tients with metastasized NSGCT (Stage II -IV) received decrease''(score of 03) to ''sharp increase''(score of four induction courses of PCT: cisplatin in combina-/3). Changes in the value of sexuality could be indition with vinblastine and bleomycin (PVB), or with cated on a 5-point scale, from ''has become far less etoposide rather than vinblastine (BEP). 60 At the Uniimportant''(score of 02) to ''has become much more versity Hospital Groningen, PCT has been used since important'' (score of /2). 1976. 61,62 If there was any residual retroperitoneal tumor tissue, surgical resection was subsequently under-Statistical Analysis taken. 53, 63 Patients with Stage I or IIA ST received RT To portray the clinical relevance of the results in interin a dose of 25 -30 grays (Gy) to the ipsilateral paraaorpretive percentages, the raw scores for the above-mental and parailiac lymph nodes. 64, 65 Patients with Stage tioned dependent variables were combined. Four-IIB -IV ST also received four courses of PVB or BEP, point scales were dichotomized into two categories: but without additional surgical intervention. scores 0 and 1 (no change and slight change), and scores 2 and 3 (moderate change and sharp change) Design were taken together. Because premature or retarded From a medical point of view, treatment with the ejaculation was indicated by only 13 patients (5%) the W&S approach is not as far-reaching as that within results of these items are described briefly, but not the other treatment approaches; after orchidectomy, used in analyses. To obtain comparable outcomes, rethe patients only have to attend regular outpatient duced ejaculation was scored as 2 and complete absence was scored as 3. Variables for which the patient check-ups. Therefore, to evaluate the possible influwas asked to indicate the amount of change were reence of the treatment modality (RT, PCT, or duced to three categories: decrease, no change, and PCT/RRRTM), the W&S group formed a very acceptincrease in the relevant aspect. able control group.
To present the average outcomes of the various scales in a comparable manner, the raw scores were Questionnaire standardized on a scale from 0 to 10. To analyze the Because there were no adequate validated questiondifferences between the various treatment groups, naires available, a questionnaire was designed in means and standard deviations (SD) of the raw scores which patients could indicate the extent to which they were used (chi square-or Mann-Whitney U test for felt their sexual functioning had changed after treatcategoric variables, and Student's t or analysis of variment for testicular cancer. Questions concerned: deance [ANOVA] for continuous variables.) A P value°c rease of sexual response (libido, sexual arousal, erec-0.05 was considered to be significant. Correlations tion, and orgasm) decrease, absence, retarded, or prewere calculated using Spearman's Rho. mature ejaculation; decrease in sexual satisfaction; changes in sexual activities; and changes in the value
RESULTS
of sexuality because of testicular cancer and its treat-Response ment. The questionnaire was returned by 287 patients (re-In addition, there were questions regarding demosponse rate, 85%). Those who did not have complete graphic variables (age, relationship, education, relimedical data (n Å 9; 2.7%), or who underwent no stangion, and work) and patients were asked if there were dard treatment (n Å 5; 1.5%), or had bilateral testicular any other physical abnormalities besides testicular cancer (n Å 9; 2.7%) were excluded. A total of 264 cancer. The questionnaire comprised a total of 31 patients (78%) remained for further analysis. items. Data on the independent variables (tumor type: NSGCT/ST, and treatment [W&S, RT, PCT, and Patient Characteristics PCT/RRRTM]) were obtained from the medical re- Table 1 provides an overview of the patient characteristics (n Å 264; 78%). There were no significant differ-cords.
/ 7b5b$$1196 07-09-97 11:10:10 cana W: Cancer ences in mean age and mean follow-up between indi-tween the 4 treatment groups with regard to these and other demographic variables. Other diseases in viduals included and not included (n Å 23; 6.8%) and nonrespondent patients (n Å 27; 8%) Of a total of 264 addition to testicular cancer were reported by 48 patients (18%); there were no significant differences be-patients, 59 had Stage I NSGCT with the W&S policy (22.5%), 41 had ST and were followed by 25 -30 Gy tween the 4 treatment groups, although the W&S group reported the fewest number of patients with adjuvant RT(15.5%), 42 had a disseminated NSGCT and were treated by PCT (16%), and another 122 PCT other diseases (n Å 6; 10%) than the other groups (RT: n Å 9; 22%; PCT: n Å 10; 24%; and PCT/RRRTM: n Å patients received adjuvant surgery (PCT/RRRTM; 46%). At the time of the study, the mean age of the 23; 19%). The diseases most frequently mentioned by the patients were: back pain (four times), stomach total patient group was 37.7 years (range, 17 -71 years; SD, 9.7 years). The mean age of the patients treated complaints (four times), Peyronie's disease (two times), cardiac problems (two times), and general fa-with RT (all ST) was 43.4 years, which was 9 years older than the mean age of the W&S group (34.2 years). The tigue (two times). four treatment groups differed significantly in mean age (P Å 0.0001). The mean follow-up period was 6.7
Changes in Sexual Functioning in the Total Patient Group and PCT/RRRTM: 3.5%). Due to the low incidence of ally higher than those of the W&S group, but only the scores for sexual activity were significantly different. In these problems, they were not analyzed any further. A decrease or absence of ejaculation was reported by 68 the group treated by PCT, the scores were considerably higher than those in the W&S group; significant differ-patients (26%); complete absence was mentioned exclusively by patients treated by PCT/RRRTM. A total of 77 ences were found for almost all variables using the nonparametric tests, but application of ANOVA cor-patients reported a reduction of ¢1 aspects (a-d) of the sexual response (29%) (ejaculation included 106 patients rected for age showed significant differences only for decreased libido, orgasm, ejaculation, and for the [40%] reporting reduction of ¢1 functions). Thirty-three patients (12.5%) were dissatisfied about their sexual life index of the cumulative scores and changes in sexual activity. The scores in the group treated by since treatment. This mainly concerned patients who reported reduction of ¢2 sexual functions (16 patients, 49%
PCT/RRRTM were generally much higher than those in the W&S group; it was surprising that on all points of this group). 34% of the patients reported a change in sexual activity (n Å 89; decrease: 23.5%, increase: 10.5%).
the scores in this group were lower than those in the PCT group. After correction for age, differences be-Changes in the value of sexuality were reported by 22% (n Å 58: decrease: 7.5%, increase: 15%). In addition to tween this group and the W&S group were significant for ejaculation, the index of the cumulative scores, outcomes of the total population, Table 2 also provides an overview of the outcomes per treatment modality.
sexual dissatisfaction, and changes in sexual activity. In addition, ejaculation in this group differed significantly from that in the RT and PCT groups (vs. RT: P Comparison of the Various Treatment Groups Å 0.000; vs. PCT: P Å 0.002; data not shown). Table 3a 
presents the results of a comparison between the W&S group versus the other treatment modalities (RT, PCT, and PCT/RRRTM). Due to the fairly wide Correlation between Dependent Variables and Covariables
variation in mean age between the various treatment groups, not only the Mann-Whitney U test was used, The correlation between the scores for the sexual response functions (libido, arousal, erection, and or-but also ANOVA corrected for age. In Table 3b the standardized mean scores of the various treatment gasm) was fairly high and these variables form a homogeneous scale (Spearman's Rho: 0.55 -0.74; Cron-modalities are presented.
The scores in the group treated by RT were gener-bach's a: 0.89), whereas the correlation between these / 7b5b$$1196 07-09-97 11:10:10 cana W: Cancer variables and ejaculation, and the item-total correla-was not significant or very low (Spearman's Rho: 0.12 -0.23) (Table 4a ). Although there were significant differ-tion of ejaculation was rather low and decreased the Cronbach's a (Spearman's Rho: 0.22 -0.33; item-total ences in age and follow-up period between the four treatment groups (Table 1) , these variables, as well as correlation: 0.37; Cronbach's a: 0.84). Sexual satisfaction showed a reasonably strong correlation with the the stage of the disease and the presence of other complaints or diseases, showed only weak correlations scores for the sexual response functions: libido, arousal, erection, and orgasm (Spearman's Rho: 0.56 -with the scores for reduced sexual functioning (Spearman's Rho: õ 0.12 -0.31) (Table 4b) of earlier studies comparing treatments. 14 -15,18 -20,22 -23 In absolute terms, the W&S patients reported the least tors, such as anxiety, impairment of physical integrity, feelings of loss, aversions, and loss of control, may play an important role. 6,14,17,20 -22 The fact that approximately 25% of patients with Stage I disease treated the patients. It shows how the subjective appraisal of with surveillance can be expected to recur and require sexuality can be influenced by testicular cancer. Nearly chemotherapy 59 may also generate anxiety and stress. 25% of the patients reported decreased sexual activity For this reason, it has been argued that patients should (23.5%), whereas ú29% reported a decrease in ¢1 asbe offered the option of initial nerve-sparing retroperipects of male sexual response (libido, arousal, erectoneal lymph node dissection (RPLND) versus surveiltion, and orgasm). Decreased libido and orgasm were lance. 68, 69 However, it appears that doctors tend to reported relatively more frequently than decreased overestimate the psychologic morbidity and underesarousal and erection. When ejaculation was included, timate the experienced physical complaints of testicu-40% of respondents reported a decrease in ¢1 sexual lar cancer patients, in particular patients treated by functions. There was a moderate correlation between W&S, 70 although the eventual psychosomatic composexual dissatisfaction and a decrease in sexual renent of these complaints remains unclear. sponse functions. Approximately 50% of the patients The RT group was an average of 9 years older who reported a decrease in ¢2 sexual functions were that the W&S group, but the 2 groups did not differ dissatisfied. Compared with the situation prior to diagsignificantly in any aspect except decreased sexual acnosis and treatment, nearly 25% of patients stated that tivity. Correlations between sexual functioning and the value of their sexuality had changed.
age were generally weak and correction of the scores Comparison of treatment modalities introduced important nuancing to the results of the total group, for age did not change the general trend. Erectile dys-/ 7b5b$$1196 07-09-97 11:10:10 cana W: Cancer function due to RT-induced vascular damage appears appear to have an inhibitory influence on sexual functioning, 76, 77 although this relation also may occur in unlikely because only a few RT patients reported erectile problems (14.5%). A large proportion of the RT reverse. 78 In addition, negative fixation on the genital region can lead to a decrease in sexual activity. 79 As group mentioned decreased libido and sexual activity (22% each). It is unlikely that these problems were in patients with gynecologic cancers, 80 changes in the experience of sexuality and sexual behavior in patients caused by low testosterone levels because generally measurements of serum testosterone are within the treated for testicular cancer can only partly be explained by biologic-organic disturbances. Although normal ranges, 42 and even very low serum testosterone levels permit normal sexual functioning. 32, 33 In this re-patients receiving PCT are at risk for sexual morbidity, changes in sexual functioning appear to be strongly spect, emotional and cognitive factors also may be decisive.
related to emotional, cognitive, and motivational aspects. 11, 56, 81, 82 In this respect, it was noteworthy that a In the group treated by PCT ({RRRTM) a limited number of patients reported erectile problems (17% decrease in one or more sexual functions led to reduced sexual satisfaction in only a limited number of and 15%, respectively), and there was no statistic significant difference compared with the W&S group. patients. 14 It is possible that after a cancer diagnosis, which carries a heavy emotional burden and involves Therefore, PCT-induced erectile dysfunction could not be proven. However, a considerable proportion of PCT a life-threatening experience, patients rebalance their emotions and cognitions, such as norms and values patients reported decreased libido (29.5%) and orgasm (28.5%). In addition, after correction for age, this group concerning sexuality and the partner relationship. 15, 18, 21 This may give rise to shifts in their out-still differed significantly from the W&S group. Theoretically, these differences may have been caused by look. 83,84 long term biologic impacts of PCT such as neuropathy and general health status, but at the same time inter-CONCLUSIONS action with emotional and cognitive factors may have A substantial proportion of the patients treated for played a decisive role in view of the life-threatening testicular cancer in the current study experienced nature of cancer in general and the drastic nature of a decrease in sexual functioning, although the ma-PCT. 15, 16, 23 The same applies to the decrease in sexual jority reported no symptoms at all. Comparisons activity, as was reported by nearly 25% of the patients.
between treatment groups introduced important For a patient undergoing a course of PCT, the situation nuancing to the results and showed significant difis more or less impossible to control because of the ferences between patient groups. Patients treated paradoxic nature of this aggressive treatment, and the by PCT ({RRRTM) reported a considerably sharper patient's unclear future. Such massive loss of control decrease in sexual functions, satisfaction, and accan give rise to passivity 71 and perhaps even to emotivity than the W&S group. Therefore, chemothertional regression. 72 apy can be considered to be the main risk factor for According to expectations, 73-75 the sharpest dea decrease in sexual functioning. crease in ejaculation was reported in the PCT/RRRTM The differences between treatment groups in group. This group was the only one that reported abreduction of sexual functions could not be attribsence of ejaculation, e.g., retrograde ejaculation. Howuted to age, the duration of follow-up, tumor stage, ever, contrary to expectations, considerably less deor the presence of other diseases, because these crease in libido, orgasm, and sexual activity was revariables showed only very weak correlations with ported (although the differences were not statistically the variables concerning sexuality. Furthermore, significant) in the group treated by PCT/RRRTM than there were no differences in demographic variables in the group treated by PCT alone. This trend underor reports of other abnormalities between the treatscores the lack of evidence for a mere biologic-organicment groups. Theoretically, treatment-related biobased decrease in sexual functioning after treatment logic-organic factors, such as hormonal, vascular, by PCT. From a psychologic point of view, chemotheror neurogenic disturbances, may be held responsiapy may give rise to uncertainty, anxiety, and passivity, ble for reduced sexual functioning, but this has yet whereas additional resection of residual tumor mass to be demonstrated. Psychologic factors appear to after chemotherapy (PCT / RRRTM) may increase play an important mediating (if not determining) feelings of recovery and certainty by its concrete effect.
role. If future studies confirm this theory, psy-This same argument has been stated with respect to chologic intervention would be of benefit for pathe discussion concerning nerve-sparing RPLND vertients with decreased sexual functioning after treatsus surveillance in Stage I NSGCT. 70 In general, uncertainty, anxiety, and loss of control ment for testicular cancer.
/ 7b5b$$1196 07-09-97 11:10:10 cana W: Cancer vivors and a control group of healthy men. Cancer 1989;
